Published in Health Policy Plan on December 07, 2012
Surprise is a Neglected Aspect of Emerging Infectious Disease. Ecohealth (2014) 1.18
Emerging and reemerging neglected tropical diseases: a review of key characteristics, risk factors, and the policy and innovation environment. Clin Microbiol Rev (2014) 0.83
One Bioregion/One Health: An Integrative Narrative for Transboundary Planning along the US-Mexico Border. Glob Soc (2015) 0.75
One Health - a strategy for resilience in a changing arctic. Int J Circumpolar Health (2015) 0.75
Implementing One Health as an integrated approach to health in Rwanda. BMJ Glob Health (2017) 0.75
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med (2002) 4.77
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis (2004) 4.55
Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Med (2008) 3.48
Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog (2012) 3.35
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol (2008) 2.32
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat Immunol (2012) 2.04
HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. J Virol (2008) 1.95
Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. J Virol (2008) 1.94
Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. J Virol (2010) 1.82
Gag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parameters. J Virol (2010) 1.81
Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J Virol (2010) 1.80
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol (2012) 1.62
HLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers. J Virol (2009) 1.54
Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol (2011) 1.45
A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis (2007) 1.41
Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. Mol Biol Evol (2009) 1.37
Transmission and long-term stability of compensated CD8 escape mutations. J Virol (2008) 1.29
Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol (2012) 1.29
HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis (2005) 1.25
Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations. PLoS One (2011) 1.24
Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. J Virol (2012) 1.20
A genome-to-genome analysis of associations between human genetic variation, HIV-1 sequence diversity, and viral control. Elife (2013) 1.19
Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences. J Exp Med (2010) 1.19
Frequent and variable cytotoxic-T-lymphocyte escape-associated fitness costs in the human immunodeficiency virus type 1 subtype B Gag proteins. J Virol (2013) 1.14
Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology (2013) 1.12
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance. J Virol (2002) 1.11
HIV evolution in response to HLA-restricted CTL selection pressures: a population-based perspective. Microbes Infect (2008) 1.10
Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. J Infect Dis (2004) 1.04
Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative study. Retrovirology (2009) 1.04
Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology (2013) 1.01
Aminopeptidase substrate preference affects HIV epitope presentation and predicts immune escape patterns in HIV-infected individuals. J Immunol (2012) 0.98
HLA class I sequence-based typing using DNA recovered from frozen plasma. J Immunol Methods (2012) 0.93
Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. J Virol (2012) 0.93
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial. J Infect Dis (2011) 0.91
Immune-mediated attenuation of HIV-1. Future Virol (2011) 0.89
Dynamic range of Nef functions in chronic HIV-1 infection. Virology (2013) 0.89
Significant reductions in Gag-protease-mediated HIV-1 replication capacity during the course of the epidemic in Japan. J Virol (2012) 0.88
Host-specific adaptation of HIV-1 subtype B in the Japanese population. J Virol (2014) 0.88
Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3. J Infect Dis (2005) 0.88
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. PLoS One (2013) 0.86
CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. AIDS Res Hum Retroviruses (2008) 0.86
HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2006) 0.84
Distinct HIV-1 escape patterns selected by cytotoxic T cells with identical epitope specificity. J Virol (2012) 0.84
Intersubtype differences in the effect of a rare p24 gag mutation on HIV-1 replicative fitness. J Virol (2012) 0.83
Structure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infection. Sci Rep (2013) 0.82
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. Antivir Ther (2003) 0.81
In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1. J Clin Microbiol (2010) 0.81
Impact of antiretroviral therapy duration and intensification on isolated shedding of HIV-1 RNA in semen. J Infect Dis (2013) 0.79
A strong association of human leukocyte antigen-associated Pol and Gag mutations with clinical parameters in HIV-1 subtype A/E infection. AIDS (2016) 0.79
Early immune adaptation in HIV-1 revealed by population-level approaches. Retrovirology (2014) 0.79
Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One (2012) 0.78
Switching and emergence of CTL epitopes in HIV-1 infection. Retrovirology (2014) 0.78
An evaluation of phylogenetic methods for reconstructing transmitted HIV variants using longitudinal clonal HIV sequence data. J Virol (2014) 0.78
Increasingly successful highly active antiretroviral therapy delays the emergence of new HLA class I-associated escape mutations in HIV-1. Clin Infect Dis (2012) 0.78
Minor contribution of HLA class I-associated selective pressure to the variability of HIV-1 accessory protein Vpu. Biochem Biophys Res Commun (2012) 0.77
A method for killer-cell immunoglobulin-like receptor (KIR) 3DL1/3DS1 genotyping using DNA recovered from frozen plasma. J Immunol Methods (2013) 0.75
Potential for immune-driven viral polymorphisms to compromise antiretroviral-based pre-exposure prophylaxis for prevention of HIV-1 infection. AIDS (2017) 0.75
HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix? AIDS (2006) 0.75
A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy. AIDS Res Hum Retroviruses (2007) 0.75